TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 58 filers reported holding TCR2 THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $50 | +51.5% | 33,116 | 0.0% | 0.00% | – |
Q4 2022 | $33 | -99.9% | 33,116 | -1.3% | 0.00% | – |
Q3 2022 | $60,000 | -41.7% | 33,561 | -5.5% | 0.00% | – |
Q2 2022 | $103,000 | -7.2% | 35,525 | -12.2% | 0.00% | – |
Q1 2022 | $111,000 | -75.8% | 40,477 | -58.8% | 0.00% | – |
Q4 2021 | $458,000 | +63.0% | 98,142 | +197.1% | 0.00% | – |
Q3 2021 | $281,000 | -59.5% | 33,032 | -21.8% | 0.00% | – |
Q2 2021 | $694,000 | -35.6% | 42,235 | -13.4% | 0.00% | -100.0% |
Q1 2021 | $1,077,000 | +205.1% | 48,779 | +326.6% | 0.00% | – |
Q4 2020 | $353,000 | +16.1% | 11,435 | -23.7% | 0.00% | – |
Q3 2020 | $304,000 | +120.3% | 14,996 | +67.2% | 0.00% | – |
Q2 2020 | $138,000 | +360.0% | 8,969 | +130.4% | 0.00% | – |
Q1 2020 | $30,000 | -82.2% | 3,893 | -67.2% | 0.00% | – |
Q4 2019 | $169,000 | +89.9% | 11,885 | +102.0% | 0.00% | – |
Q3 2019 | $89,000 | +456.2% | 5,885 | +402.1% | 0.00% | – |
Q2 2019 | $16,000 | -60.0% | 1,172 | -49.4% | 0.00% | – |
Q1 2019 | $40,000 | – | 2,318 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |